Levepsy 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure activity. This medication is typically prescribed as adjunctive therapy but may also be used as monotherapy depending on clinical judgment. Levepsy 500 is absorbed rapidly after oral administration, with peak plasma concentrations achieved within one hour, and it is primarily excreted unchanged via the kidneys. Dosage should be individualized based on patient response, renal function, and tolerability, with careful titration to minimize adverse effects. Common side effects include somnolence, dizziness, headache, and fatigue, while serious adverse reactions may involve behavioral changes, mood disturbances, or hypersensitivity reactions. Regular monitoring of clinical status and renal function is recommended during therapy. Levepsy 500 Tablet should be used cautiously in patients with renal impairment and is contraindicated in individuals with known hypersensitivity to Levetiracetam or any component of the formulation. Patient adherence to prescribed dosing schedules is essential to optimize therapeutic outcomes and reduce seizure frequency.